Key facts
- It has raised $182.1M; the latest was Later Stage VC ($75.0M) in Sep 2025.
- Notable investors include Hongshan Capital Group, Connecticut Innovations, Canaan Partners, Osage University Partners, Samsara BioCapital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Normunity
- ·The full record, as it builds
Funding rounds
No funding rounds for Normunity are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Normunity
Operator of a biotechnology company intended to create precision immuno-oncology medicines. The company's medicine drives the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function, enabling doctors to treat cancer by restoring the state of normal immunity.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2020
- Employees
- 23
- Website
- normunity.com/
- Ownership
- Privately Held (backing)
Normunity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Normunity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Normunity in its N-PORT filings yet. We sweep new filings monthly.